| MUNC13-1 Protein | |
|---|---|
| Gene | [UNC13A](/genes/unc13a) |
| UniProt ID | [Q9UJU2](https://www.uniprot.org/uniprot/Q9UJU2) |
| PDB Structures | Not determined (large multi-domain protein) |
| Molecular Weight | ~1993 kDa (full-length) |
| Subcellular Localization | Presynaptic active zone |
| Protein Family | MUNC13/MiRP family |
MUNC13-1 Protein is a protein encoded by the UNC13A gene. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
MUNC13-1 (UNC13A) is a massive presynaptic protein essential for synaptic vesicle priming and neurotransmitter release[1]. The protein contains multiple functional domains including an N-terminal C1 domain (diacylglycerol binding), a C2B domain (Ca2+/phospholipid binding), a MUN domain (mediating SNARE complex assembly), and multiple other regions involved in protein-protein interactions[2]. The C1 domain binds diacylglycerol (DAG) and phorbol esters, while the C2B domain binds Ca2+ and phospholipids, allowing regulation of MUNC13-1 activity by second messengers[3]. The central MUN domain is crucial for mediating the transition of synaptic vesicles from the docked state to the fusion-ready primed state by facilitating SNARE complex assembly[4].
MUNC13-1 is a key component of the presynaptic active zone, where it plays an essential role in synaptic vesicle priming and short-term synaptic plasticity[1:1]. The protein is required for the priming of synaptic vesicles to a readily releasable state, a process that precedes fusion and allows rapid neurotransmitter release upon stimulation[5]. MUNC13-1 interacts with multiple active zone proteins including RIM, ELKS, and Bassoon, forming a molecular scaffold that organizes the presynaptic release machinery. The protein's C1 and C2B domains allow it to serve as a sensor of neuronal activity, integrating Ca2+ and DAG signaling to regulate release probability and short-term plasticity[6]. MUNC13-1 is essential for several forms of synaptic plasticity including facilitation, depression, and augmentation.
MUNC13-1 (UNC13A) is one of the most significant genetic risk factors for sporadic ALS identified through genome-wide association studies[7]. Common polymorphisms in the UNC13A gene are associated with increased risk for both sporadic ALS and frontotemporal dementia (FTD)[8]. The risk alleles affect mRNA splicing and may lead to reduced MUNC13-1 expression or altered function. Since MUNC13-1 is critical for synaptic vesicle priming, reduced function could impair neurotransmission at the neuromuscular junction and corticomotor synapses, contributing to motor neuron degeneration[9]. Studies in ALS models suggest that MUNC13A variants may interact with TDP-43 pathology to exacerbate disease progression.
The UNC13A gene is associated with risk for frontotemporal dementia, particularly the TDP-43 pathological subtype[10]. Genetic variants in UNC13A increase FTD risk through mechanisms similar to ALS, potentially affecting synaptic function in cortical neurons. The protein may be involved in the synaptic dysfunction that occurs early in FTD pathogenesis, before overt neuronal loss. MUNC13A risk variants may also influence the spread of TDP-43 pathology through synaptic connections[11].
Altered MUNC13-1 expression and function may contribute to synaptic dysfunction in Parkinson's disease[12]. The protein plays roles in dopaminergic synaptic transmission in the striatum, and dysregulation could affect dopaminergic signaling. MUNC13-1 may also interact with proteins involved in PD pathogenesis, including α-synuclein. Studies suggest that restoring or enhancing MUNC13-1 function could be a therapeutic strategy for PD, although this remains exploratory[13].
Genetic variants in UNC13A have been associated with schizophrenia risk in genome-wide studies[14]. The protein's critical role in synaptic transmission and plasticity makes it a candidate for the synaptic dysfunction hypothesis of schizophrenia. Altered MUNC13-1 function could contribute to the working memory and cognitive deficits seen in schizophrenia patients[15].
Therapeutic strategies targeting MUNC13-1 in neurodegeneration include[16][17]:
CCL5/RANTES in Neuroinflammation and Neurodegeneration. ↩︎ ↩︎
Ma C, et al. Munc13 mediates the transition from the docked to the readily releasable vesicle pool. Nature. 2011. ↩︎
Betz A, et al. Munc13-1 functions as a Ca2+ and diacylglycerol-dependent facilitator of neurotransmitter release. Journal of Physiology. 2001. ↩︎
Brose N, et al. Munc13: priming synaptic vesicles for fusion. Cell. 2000. ↩︎
van Es MA, et al. Genetic variation in UNC13A influences ALS susceptibility. Lancet Neurology. 2008. ↩︎
Diekstra FP, et al. UNC13A is a modifier of survival in ALS. Neurology. 2012. ↩︎
Oskarsson B, et al. ALS-associated UNC13A variant affects splicing. Nature Genetics. 2018. ↩︎
Ferrari R, et al. UNC13A in FTD and ALS. Journal of Neurology, Neurosurgery & Psychiatry. 2015. ↩︎
Neumann M, et al. TDP-43 pathology in FTD. Current Opinion in Neurology. 2006. ↩︎
Calo L, et al. Munc13 in dopaminergic signaling. Journal of Parkinson's Disease. 2017. ↩︎
Picconi B, et al. Synaptic dysfunction in Parkinson's disease. Advances in Experimental Medicine and Biology. 2014. ↩︎
Psychiatric GWAS Consortium. Genome-wide association study of schizophrenia. Nature. 2009. ↩︎
Fromer M, et al. Gene expression in schizophrenia. Nature Neuroscience. 2014. ↩︎
Brose N, et al. Molecular mechanisms of synaptic vesicle priming. Current Opinion in Neurobiology. 2015. ↩︎
Siksou L, et al. Molecular architecture of the presynaptic active zone. Journal of Neurochemistry. 2008. ↩︎